. Dose response with increasing concentrations of Vemurafenib on MU cells. 2000 MU parental and resistant melanoma cells were plated in 96-well plates and grown for 24 h. Cells were then treated with vemurafenib from concentrations ranging from 0.01 to 0.5 μM for 96 h after which an MTT viability assay was performed. Growth of parental (18-69%) and resistant (13-77%) cells was inhibited in a comparable manner. Data are representative of three independent experiments. Wnt inhibitors. MU-P/R cells were plated and after 24 h starved overnight in media supplemented with 0.5% BSA, and then treated with or without a combination of everolimus (1 μM), SU11274 (5 μM), and XAV939 (15 μM). Cells were stimulated with 40 ng/ml of HGF for 7.5 min, after which immunoblotting analysis was performed. (A) Upregulation of p-c-Met (Y1003) (3.0-fold) and p-p70S6kinase (1.5-fold) was seen after treatment with HGF in MU-R cells, as compared to MU-P cells. Upregulation of p-Akt (1.5 and 4.5-fold, ± HGF) was observed in MU-R cells as compared to MU-P cells, and upregulation of p-Akt (3.0-and 2.5-fold, ± HGF) in MU-R cells was inhibited after combination treatment as compared to untreated MU-R cells. (B) Upregulation of pLRP6 (1.5-fold), GATA-6 (4.0-fold), and p-ERK (3.5-fold) was observed in MU-R cells in the absence of HGF, as compared to MU-P cells. Furthermore, upregulation of pLRP6, GATA-6, and p-ERK in MU-R cells ± HGF was inhibited with combination treatment, as compared to untreated MU-R cells. Downregulation of Axin1 (3.0-and 1.5-fold, ± HGF), a negative regulator of Wnt signaling, was observed in MU-R cells as compared to MU-P cells, and Axin1 levels in MU-R cells were comparable to levels in MU-P cells after treatment with combination therapy. Figure S4 . Treatment with triple combination therapy decreases cell proliferation in c-Met resistant cell lines. 70 000 MU-P/R and RU-P/R melanoma cells were plated in 35 mm petri dishes and grown for 24 h. Cells were then treated with everolimus (1 μM), SU11274 (5 μM), and XAV939 (15 μM), individually and in combinations, and after 96 h cellular proliferation was evaluated with trypan blue exclusion. (A) Growth of RU-R cells was inhibited by 93% when using a triple combination of everolimus (1 μM), SU11274 (5 μM), and XAV939 (15 μM). (B) In MU-R cells, 69% inhibition of growth occurred when a combination of everolimus, SU11274, and XAV939 was used. Significant differences (RU-R or MU-R, P < 0.001) were observed between treatment with single drug (S, E, and X), double drug combinations (S+E, S+X, and E+X) and triple drug combination (S+E+X), as seen by repeated measures ANOVA with multiple pairwise comparisons as well as custom contrasts with Bonferroni adjustments. Statistical significance was determined with α at 0.05. The experiment was performed in quadruplicate.
